Skip to main content

Eurobio Scientific and the Hospices Civils de Lyon join forces to develop a bank of anti-SARS CoV-2 antibodies

Written by Customer Service on . Posted in Public Companies.

Eurobio Scientific and the Hospices Civils de Lyon join forces
to develop a bank of anti-SARS CoV-2 antibodiesCreation of a bank of human monoclonal antibodies for research, diagnostic and therapeutic purposesUse of proprietary HuBBB technology from Eurobio ScientificSupply of donor samples by the Hospices Civils de Lyon (HCL)Paris, May 13, 2020 – 5 :45 pmEurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces today that it has partnered with HCL to conduct an observational clinical study with the primary objective of creating a reference bank of antibodies anti-SARS CoV-2, the virus responsible for Covid-19 disease. This study started on April 29 and is scheduled for completion in July 2020.Reference antibodies: a critical requirementThe antibodies generated during an infection by a virus can be of several types: those which neutralize the virus and are therefore of therapeutic interest, and those which amplify the symptoms of the disease, in particular by facilitating the penetration of the virus into the cells.The development of vaccines against the virus therefore requires the availability of a reference antibody bank in order to better identify the antibodies induced and avoid potentially harmful types. This bank also makes it possible to carry out more precise diagnostic tests which should make it possible to predict the course of the disease according to the populations of antibodies detected.Implementation of proprietary technologyThe clinical study1 plans to recruit convalescent patients who did contract the virus, without hospitalization or with admission in emergency to the infectious diseases department of the Croix-Rousse Hospital in Lyon. Three objectives have been defined: generate the reference antibody bank, compare the antibodies of pauci-symptomatic patients and emergency patients, compare the effectiveness for neutralizing the virus of the patients’ natural antibodies and the reference antibodies generated.As part of this study, Eurobio Scientific will use its proprietary HuBBB technology to immortalize cells of the human immune system (B cells) to make them produce antibodies of interest.The antibody bank thus created will reinforce the catalog of antibodies, marketed by Eurobio Scientific within its division for Life Sciences Research, or licensed to vaccine manufacturers, and allow it to have proprietary antibodies for future diagnostic tests.Denis Fortier, Deputy General Manager of Eurobio Scientific says: “Clearly in the current epidemic situation, undertaking such a project appeared to us as an urgent necessity. Moreover, it fits perfectly as the first project of the collaboration that we are currently setting up with HCL that I thank, as well as the team of Pr. Pierre Miossec and Dr. Frédéric Coutant who helped us to get started so quickly .”  Next financial meeting
Eurobio Scientific 2020 annual shareholders meeting: June 23, 2020

1 For more information, see https://clinicaltrials.gov/ct2/show/study/NCT04354766
Attachment200513PR-Eurobio Scientific HCL_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.